Abstract
Complications following allogeneic hematopoietic cell transplantation (alloHCT) continue to be a significant challenge that often result in significant morbidity/mortality and increased healthcare utilization and cost. In this study, we analyzed the impact of post-alloHCT complications on healthcare utilization and cost during first year post-transplant. We analyzed data on 240 pediatric patients. Complications analyzed included kidney injury, liver injury, lung injury, viral infections, bacterial infections, fungal infections, and acute graft-versus-host disease (GVHD). Patients were divided into three groups based on the number of complications (0–1, 2–3, and >3). Cost was estimated from charges recorded in the Pediatric Health Information System database and hospital accounting records. Patients with >3 complications had higher healthcare utilization and cost, primarily driven by inpatient hospitalization and intensive care unit admissions. Multivariable analysis of risk factors identified bacteremia ($90,166, SE = 26,636, p < 0.001), lung injury ($108,529, SE = 28,196, p < 0.001), liver injury ($90,805, SE = 28,660, p = 0.002), and grade II–IV aGVHD ($137,866, SE = 28,472, p < 0.001) as associated with significantly increased cost. Our study highlights the significant impact complications have on the overall cost of alloHCT. The identification that complications associated with high morbidity (aGVHD, pulmonary disease) are also associated with the highest financial burden emphasizes the need for future research in these areas to expand management options and improve outcomes for our patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004-2007: Statistical Brief #82. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD; 2006.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:805–13.
Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. 2012;120:1545–51.
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transpl. 2008;14:197–207.
Barrell C, Dietzen D, Jin Z, Pinchefsky S, Petrillo K, Satwani P. Reduced-intensity conditioning allogeneic stem cell transplantation in pediatric patients and subsequent supportive care. Oncol Nurs Forum. 2012;39:E451–8.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
Smith AR, Majhail NS, MacMillan ML, DeFor TE, Jodele S, Lehmann LE, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood. 2011;117:2728–34.
Satwani P, Bavishi S, Jin Z, Jacobson JS, Baker C, Duffy D, et al. Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. Biol Blood Marrow Transpl. 2011;17:1472–80.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.
Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118:4242–9.
Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, et al. Risk factors and utility of a risk-based algorithm for monitoring cytomegalovirus, epstein-barr virus, and adenovirus infections in pediatric recipients after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2016;22:1646–53.
Chang AK, Foca MD, Jin Z, Vasudev R, Laird M, Schwartz S, et al. Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: a single-center experience. Am J Infect Control. 2016;44:1650–5.
Bourgeois W, Ricci A, Jin Z, Hall M, George D, Bhatia M, et al. Health care utilization and cost among pediatric patients receiving unrelated donor allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2019;54:691–9.
Consumer Price Index [Internet]. U.S. Bureau of Labor Statistics. U.S. Bureau of Labor Statistics [cited 2017 Sep 4]. https://data.bls.gov/pdq/SurveyOutputServlet.
Rangarajan HG, Smith LC, Stanek JR, Hall M, Abu-Arja R, Auletta JJ, et al. Increased health care utilization and costs during allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in adolescents and young adults compared with children: a multicenter study. Biol Blood Marrow Transpl. 2019;25:1031–8.
Ederhof M, Ginsburg PB. Improving Hospital Incentives with better cost data. N Engl J Med. 2017;376:1010–1.
Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010;54:138–43.
Rastogi S, Ricci A, Jin Z, Bhatia M, George D, Garvin JH, et al. Clinical and economic impact of cytomegalovirus infection among children undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2019;25:1253–9.
Ricci A, Jin Z, Broglie L, Bhatia M, George D, Garvin JH, et al. Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:384–92.
Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transpl. 2009;15:564–73.
Majhail NS, Mau LW, Denzen EM, Arneson TJ. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database. Bone Marrow Transpl. 2013;48:294–300.
Majhail NS, Mau LW, Chitphakdithai P, Payton T, Eckrich M, Joffe S, et al. National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery. Biol Blood Marrow Transpl. 2015;21:1308–14.
Ricci A, Jin Z, Broglie L, Bhatia M, George D, Garvin JH, et al. Healthcare utilization and financial impact of acute-graft-versus host disease among children undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55:384–92.
Shah GL, Majhail N, Khera N, Giralt S. Value-based care in hematopoietic cell transplantation and cellular therapy: challenges and opportunities. Curr Hematol Malig Rep. 2018;13:125–34.
Acknowledgements
We would also like to thank Stephanie Kjelleren Conner, MHSA, and Fisnik Prishtina for providing outpatient financial data.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ricci, A., Jin, Z., Bourgeois, W. et al. Financial impact of post-transplant complications among children undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 55, 1421–1429 (2020). https://doi.org/10.1038/s41409-020-0899-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0899-0
This article is cited by
-
Post-alloHCT complications in children are costly
PharmacoEconomics & Outcomes News (2020)